Welcome to our dedicated page for REGENTIS BIOMATERIALS LTD. SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials Ltd. reports that its Adjourned Annual General Meeting of Shareholders held on July 9, 2026 approved all fourteen proposals presented to shareholders. The proposals, which were outlined in the company’s May 28, 2026 Notice and Proxy Statement and a June 4, 2026 amended notice, each received the required majority support.
Regentis Biomaterials Ltd. is registering for resale up to 3,807,143 Ordinary Shares by selling shareholders, including shares issued in a June 17, 2026 private placement and shares issuable upon exercise of related warrants.
The prospectus states 7,023,921 Ordinary Shares outstanding as of July 8, 2026. The company will not receive proceeds from resale by the selling shareholders, although it may receive approximately $8.21 million if the offered warrants are exercised for cash in full.
Regentis Biomaterials Ltd. convened its Annual General Meeting of Shareholders on July 2, 2026, but the meeting was adjourned for one week due to lack of quorum. The meeting will be reconvened on July 9, 2026 at 3:00 p.m., Israel time, at the offices of the Company’s attorneys in Tel Aviv.
Regentis Biomaterials Ltd. entered into definitive agreements for a private placement expected to raise approximately $6.5 million in gross proceeds. The company will issue 1,844,543 ordinary shares and pre-funded warrants for up to 12,600 shares, together with ordinary warrants for up to 1,857,143 shares at a combined purchase price of $3.50 per ordinary share and warrant, and $3.4999 per pre-funded warrant and warrant.
Pre-funded warrants are immediately exercisable at $0.0001 per share with no expiry until fully exercised, while ordinary warrants are immediately exercisable at $4.20 per share and expire five years after issuance. Placement agent ThinkEquity will receive cash fees totaling 8% of gross proceeds plus up to $180,000 in expense reimbursement and warrants to purchase 92,857 shares at $4.375 per share. Net proceeds are earmarked to fund the pivotal GelrinC trial, U.S. FDA pre-market approval preparation, Gelrin platform development, operational readiness, European market entry, and general corporate purposes.
Regentis Biomaterials Ltd., a foreign private issuer based in Israel, reports that it has requested withdrawal of its Registration Statement No. 333-295510 on Form F-1, effective June 15, 2026. The company has decided not to pursue the public offering that was planned under this registration.
Regentis Biomaterials Ltd. filed Amendment No. 1 to its Form F-1 (Registration No. 333-295510) to file an updated Exhibit 23.1 and to amend and restate the Exhibit Index in Part II. The amendment expressly omits prospectus changes in Part I and does not change the offering terms disclosed earlier.
The filing also discloses prior unregistered financings and convertible loans, including aggregate convertible financings of $900,000 (2020 CLAs) and $835,000 (2021 CLAs), conversions into Ordinary Shares, multiple bridge loans and CEO loan arrangements with interest at 8% and related warrants. Signature pages and U.S. authorized representative attestations are included.
Regentis Biomaterials Ltd. plans to begin European surgeon training for its GelrinC knee cartilage repair implant in the third quarter of 2026, advancing preparations for commercial rollout in Europe, where the product holds CE Mark approval. Initial hands-on training will occur at Humanitas Research Hospital in Milan, with additional sessions across other European markets. The company is building a network of European Centers of Excellence to support surgeon education, clinical guidance, and knowledge sharing around GelrinC. GelrinC is an off-the-shelf, cell-free hydrogel implant with a roughly 10-minute, single-step procedure, positioned as an alternative to microfracture and complex cell-based therapies. Regentis is targeting an estimated $3 billion U.S. market of about 470,000 annual knee cartilage repair cases, and GelrinC is also being evaluated in a pivotal FDA study that has completed more than 50% of enrollment.
Regentis Biomaterials Ltd. filed an amended Form 6-K to update materials for its Annual General Meeting on July 2, 2026. Shareholders will vote on re-electing Class I directors, ratifying external directors Pini Ben Elazar and Susan Alpert, and adopting a new compensation policy.
The agenda also includes multiple equity awards: options for directors and external directors, including 24,826 options per recipient at an exercise price of $2.16 per share, an 8,313-option top-up grant to Pini Ben-Elazar at NIS 0.01, and warrants to purchase 31,250 and 12,500 ordinary shares for Ehud Geller and Jeff Dykan at NIS 0.01 per share. Shareholders will vote on reappointing Deloitte Israel & Co. as auditor and reviewing 2025 financial statements. As of May 26, 2026, 5,179,378 ordinary shares were issued and outstanding.
Regentis Biomaterials Ltd. has called its Annual General Meeting for July 2, 2026 at 3:00 p.m. Israel time in Tel Aviv. Shareholders as of the June 9, 2026 record date will vote on re-electing two Class I directors, adopting a new compensation policy, and re-appointing Deloitte Israel as auditor for 2026.
The agenda includes equity-based pay items: option grants of 24,826 options each to three non-executive directors at an exercise price of US$2.16, a fully vested top-up grant of 8,313 options to director Pini Ben-Elazar at NIS 0.01, and replacement warrants to purchase 31,250 and 12,500 ordinary shares for related-party lenders at NIS 0.01 per share. The board unanimously recommends voting in favor of all proposals.